ADBE vs MRK: Which Is the Better Buy?
Side-by-side comparison of Adobe Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Adobe Inc. · Technology
$248.16
+163.1% upside to fair value
High Conviction
Grade B
VS
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
ADBE has more upside to fair value
(+163.1%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ADBE |
MRK |
| Current Price |
$248.16 |
$121.42 |
| Fair Value Estimate |
$653.00 |
$118.00 |
| Upside to Fair Value |
+163.1%
|
-2.9%
|
| Market Cap |
$101.2B |
$300.2B |
| Forward P/E |
14.1x
|
14.0x
|
| EV / EBITDA |
—
|
11.8x
|
| Price / Sales |
4.1x
|
4.1x
|
| Price / FCF |
9.8x
|
21.4x
|
| Revenue Growth YoY |
+3.3%
|
+1.3%
|
| Gross Margin |
89.1%
|
81.5%
|
| Operating Margin |
36.6%
|
41.2%
|
| Return on Equity |
62.3%
|
34.7%
|
| Dividend Yield |
— |
3.1% |
| FCF Yield |
10.2%
|
4.7%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Adobe Inc. develops industry-leading creative software, digital experience platforms, and publishing tools, powering digital content creation and marketing for professionals worldwide. The business excels with high gross margins above 89%, a sticky subscription model driving recurring revenue over $17B ARR, and dominant moats in digital media, though it faces intensifying AI competition and slowi…
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Accumulation Zones
| Metric |
ADBE |
MRK |
| Zone Low |
$490.00 |
$88.00 |
| Zone High |
$555.00 |
$100.00 |
| In Buy Zone? |
Yes
|
No
|